Hangzhou Tigermed Consulting Co., Ltd

¥51.61As of Sun 8 Nov 2026, 12:00 UTC
SZSE:300347Healthcare
Country China
PE (Fwd) •••
TSR 10Y CAGR 10.28%
Div yield 0.24%
ROE (1.71%)
Diagnostics & Research
Beta (5Y) 0.44
PE TTM —
TSR TTM (13.56%)
Mkt cap ¥40.80B
ROIC 3.14%
SE Grade™
Value
Quality
Moat
Consensus
Reference
¥60
15.64%
(72.41%)
Hold 9|1|2|5|9
4Q25
1Q26
2Q26
3Q26
Earnings per share¥
0.75
0.76
0.76
0.74
11.83%
13.54%
13.02%
0.98%
Revenue¥B
3.953
4.160
4.368
4.398
10.83%
13.62%
14.25%
17.63%
Peers (US$6.115B)
Cap (US$)
PE
4.511B
29.39x
5.981B
—
Capital
TTM
5Y
10Y
Leveragex
0.631
0.091
0.090
EBIT/Intx
0.302
0.810
0.701
Own earn%
24.51
105.04
53.59
Sh yield%
28.92
36.14
32.84
Owners
Insiders/Inst%
14.35
52.69
Short interest%
1.78
SBC / revenue%
1.88
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
4
Op margin range%
7–14
$1 testx
—
Incr. ROIC%
3